Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.

Abstract excerpt

c-Met kinase has been considered as an attractive target for developing antitumor agents. The strong interactions between Tyr1230 and the inhibitors emphasized its importance for ligand binding. The clinically related Tyr1230 mutations have made negative impacts on current c-Met kinase inhibitors, especially the exquisitely selective ones, like PF-04217903, while the multi-targeted inhibitors, like Crizotinib,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Crizotinib
• Share to Hydrogen Bonding